Cardiff Oncology, Inc. (CRDF) News
Filter CRDF News Items
CRDF News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CRDF News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CRDF News From Around the Web
Below are the latest news stories about CARDIFF ONCOLOGY INC that investors may wish to consider to help them evaluate CRDF as an investment opportunity.
While institutions own 25% of Cardiff Oncology, Inc. (NASDAQ:CRDF), retail investors are its largest shareholders with 57% ownershipKey Insights Significant control over Cardiff Oncology by retail investors implies that the general public has more... |
Cardiff Oncology price target raised to $10 from $7 at Piper SandlerPiper Sandler raised the firm’s price target on Cardiff Oncology (CRDF) to $10 from $7 and keeps an Overweight rating on the shares. The company reported initial data from its ongoing randomized Phase II trial of onvansertib in RAS-mutated mutated metastatic colorectal cancer and the early randomized dataset seems to clearly support the hypothesis that onvansertib on top of chemotherapy provides meaningful clinical benefit, the analyst tells investors in a research note. Piper sees the data as m |
Cardiff Oncology Reports Promising Phase 2 Trial ResultsAn update from Cardiff Oncology ( (CRDF) ) is now available. Cardiff Oncology has reported promising initial results from its Phase 2 trial (CRDF-004) testing onvansertib with standard care in first-line RAS-mutated metastatic colorectal cancer. The data suggests enhanced efficacy with onvansertib, showing higher overall response rates compared to standard treatments alone. This development could represent a significant breakthrough for investors watching the oncology sector, though risks and un |
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct OfferingSAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (“Cardiff Oncology” or the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the pricing of an underwritten offering of 15,384,619 shares of its common stock at an offering price of $2.60 per share, before deducting underwriting discounts and commissions. All of the shares of common stock are being offered by the Comp |
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial- Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control arm - - In the experimental arms, 30mg dose of onvansertib demonstrated a higher ORR compared to 20mg dose of onvansertib (64% vs. 50%) with deeper tumor regression in the 30mg arm - - Onvansertib was well tolerated at both doses - - Additional clinical data from CRDF-004 trial expected in 1H 2025 - |
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC- Protects the use of onvansertib in combination with standard of care in the KRAS mutated mCRC setting through 2043 - SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the United States Patent and Trademark Office (USPTO) has issued to Cardiff Oncology U.S. patent No. 12,144,813 with an expected expiration date of no earlier th |
Cardiff Oncology Third Quarter 2024 Earnings: Beats ExpectationsCardiff Oncology ( NASDAQ:CRDF ) Third Quarter 2024 Results Key Financial Results Net loss: US$11.9m (loss widened by... |
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update- Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bev in second-line KRAS mutant mCRC in the peer-reviewed Journal of Clinical Oncology - - Initial data readout from first-line RAS-mutated mCRC randomized CRDF-004 trial expected by the end of 2024- - Projected runway with current cash resources into Q1 2026 - SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition |
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC - - Post hoc analysis resulted in a 7.7-fold higher clinical benefit in bev-naïve patients with an ORR of 77% compared to 10% in bev-exposed patients - - Results from this trial, along with translational studies, supported the transition of clinical development of onvansertib to first-line RAS-mutant mCRC - - Initial readout f |
3 US Penny Stocks With Market Caps Over $40MAs the U.S. stock market attempts to recover from a recent sell-off, major indexes like the Dow Jones and S&P 500 have shown mixed performance, reflecting investor uncertainty amid fluctuating economic indicators. In such a climate, investors often seek opportunities in less conventional areas of the market, including penny stocks. Despite their outdated name, penny stocks represent smaller or newer companies that can offer significant growth potential when backed by strong financials. |